Drug Science Announce a 20,000 Patient UK National Medical Cannabis Pilot: Project TWENTY21

Drug Science’s newly formed medical cannabis working group, which includes the United Patients Alliance, several academic researchers and several medical cannabis companies, is launching the UK’s first national pilot for medical cannabis: Project TWENTY21

Project TWENTY21 aims to enrol 20,000 patients into the pilot before the end of 2021, using a real word data patient registry, to assess efficacy, safety, QALYs, and patient reported outcomes in those prescribed medical cannabis

Drug Science believes that the benefit / risk profile of medical cannabis in certain disorders, and as a treatment for certain conditions, is favourable. The risk of continued prohibitionist approach to medical cannabis increases harms by driving patients to the illicit market, with its attendant harms from cannabis of unknown strength and content as well as fuelling an illicit supply chain that will be difficult if not impossible to dismantle in the future

Project TWENTY21 has already received support from several medical cannabis companies including Althea, Alta-Flora and Cannuba, who will provide medical supplies and other support, and will be launched officially on 18th July 2019 in London

Read the full press release here